Truist Cuts PT to $89; Goldman Lowers to $95 with High-Teens Upside
Truist Financial cut Edwards Lifesciences’s price target from $92 to $89 and kept a Hold rating after Q4 revenue beat forecasts with double-digit TAVR growth, but profits did not improve. Goldman Sachs maintained a Buy rating while lowering its target to $95, suggesting high-teens upside from heart valve products.
1. Analyst Ratings and Price Targets
On February 11, Truist Financial trimmed Edwards Lifesciences’s price target from $92 to $89 and reaffirmed a Hold rating, implying roughly 11% upside. Goldman Sachs also lowered its target from $108 to $95 on the same day, maintaining a Buy stance with high-teens upside projections.
2. Q4 Financial Performance
Edwards delivered fourth-quarter revenue above consensus, driven by double-digit growth in its transcatheter aortic valve replacement (TAVR) segment. However, operating margins remained under pressure and net profits did not increase despite the top-line beat.
3. Market Position and Outlook
The company’s leadership in heart valve repair and critical care monitoring underpins analyst forecasts. Expected tailwinds from procedural adoption, backlog growth and new product rollouts support the projected upside through the coming year.